Our Company / Alfasigma at glance
Pharmaceuticals
with passion
Alfasigma is one of the top 5 pharmaceutical companies in Italy, with a turnover in 2022 exceeding 1.2 billion euro. It’s a private company with more than 75% owned by the family of the founder. The Alfasigma legacy is firmly anchored in a long lasting heritage of innovation and success, beginning in 1948 in Bologna (Italy) thanks to Marino Golinelli, entrepreneur and philanthropist, who recently passed away at the age of 101.
From the beginning Alfasigma has always pursued a twofold strategy:
– internally, a strong focus on Research & Development and Manufacturing around some proprietary
molecules, some of which represent more than 50% of the sales;
– externally, developing a robust strategy of mergers and acquisitions of other Italian and international companies (Sigma Tau, Pamlabs, Sofar).
Currently Alfasigma has around 3.000 employees.
With an extensive presence in the international market, Alfasigma can count on a large number of direct branches in 17 countries, 2 Research & Development centers, 6 manufacturing plants, as well as on a network of top-level distributors which guarantee its products distribution on five continents and in more than 100 countries.
Alfasigma, leader in the gastrointestinal area, has a portfolio that ranges from prescription specialties to self-medication products, up to nutraceuticals.
Geographic coverage


Subsidiaries

Distributors
100 countries
Distributors
17 countries
Subsidiaries
Belgium
China
Czech Republic
France
Germany
Italy
Mexico
Netherlands
Poland
Portugal
Romania
Russia
Slovak Republic
Spain
Switzerland
Tunisia
USA
Turnover
€ 1.212
millions in 2022
5 proprietary molecules
Rifaximin, Sulodexide, Carnitine, L-Methylfolate, Parnaparin
Contract Manufacturing – Business Unit

2
R&D centers

6
Manufacturing plants

22
Subsidiaries worldwide
Headcount

3000
Workforce

46%
Male

54%
Female

1800
Domestic

1200
International